Form D · Biotechnology
Edesa Biotech, Inc.
Markham, A6 · CIK 0001540159
Offering snapshot reported Jun 26, 2026 · SEC filing
- Reported sold
- $3.5M Offering amount: $3.5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 16, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2026 | Initial | $3,499,986 | No comparison | 4 | SEC filing |
| Feb 14, 2025 | Initial | $15,000,000 | No comparison | 15 | SEC filing |
| Apr 5, 2022 | Initial | $0 | No comparison | 1 | SEC filing |
| Jul 21, 2016 | Initial | $6,750,000 | No comparison | 4 | SEC filing |
| Oct 3, 2013 | Amendment | $12,000,000 | No comparison | 50 | SEC filing |
| Sep 3, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 11, 2013 | Initial | $1,613,700 | No comparison | 22 | SEC filing |
| Jan 15, 2013 | Initial | $504,596 | No comparison | 9 | SEC filing |
| Oct 31, 2012 | Initial | $1,005,800 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-588852
Source: Form D, filed Jun 26, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory T. Baxter | Director |
| Mary Catherine Brisson | Executive |
| Michael Brooks | Executive |
| Darrell H. Brookstein | Executive |
| Jennifer Chao | Director |
| Tessie M. Che | Director |
| Herbert S. Chow | Executive |
| Joan Chypyha | Director |
| Scott Davis | Executive |
| Malcolm Lawrence Gefter | Director |
| David Louis Hill | Director |
| Lorin Johnson | Director |
| Stephen Lemieux | Executive |
| David Liu | Director |
| Sean Mac Donald | Director |
| Patrick Marshall | Director |
| Mark A. Mc Partland | Executive |
| Daniel E. Morse | Director |
| Kathi Niffenegger | Executive |
| Pardeep Nijhawan | Director, Executive |
| Frank Oakes | Director |
| Charles Olson | Director |
| Paul Pay | Director |
| Mayank D. Sampat | Director |
| Carlo Sistilli | Director |
| John Sievert Sundsmo | Executive |
| Peter Weiler | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Spy Court
Markham, A6, L3R 5H6
Phone: 289-800-9600
Markham, A6, L3R 5H6
Phone: 289-800-9600